Biohaven's spinal muscular atrophy drug fails to meet study goal
Biohaven said on Monday its experimental treatment for a rare neuromuscular disorder failed to significantly improve motor function in a late-stage trial, sending the shares of rival Scholar Rock, ...
kalkinemedia7h
Biogen’s Stock Outlook: Analysts’ Views on Its Future Performance
Highlights:,Biogen Inc. (BIIB) has underperformed the broader market and key healthcare ETFs in recent years.,The company’s ...
Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?
Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...
Business Insider10h
Jefferies Remains a Buy on Biogen (BIIB)
Jefferies analyst Michael Yee maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $250.00. The company’s shares opened today at $159.99. Don't Miss our Black ...
Mizuho Lowers Biogen (NASDAQ:BIIB) Price Target to $207.00
Biogen (NASDAQ:BIIB – Free Report) had its price objective decreased by Mizuho from $251.00 to $207.00 in a research note published on Thursday,Benzinga reports. Mizuho currently has an outperform ...